1-5 of 5
Judy-Anne W Chapman
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial

Clinical Trials & Observations
A. Keith Stewart, Suzanne Trudel, Nizar J. Bahlis, Darrell White, Waleed Sabry, Andrew Belch, Tony Reiman, Jean Roy, Chaim Shustik, Michael J. Kovacs, Morel Rubinger, Guy Cantin, Kevin Song, Kirsty A. Tompkins, Deb C. Marcellus, Martha Q. Lacy, Jonathan Sussman, Donna Reece, Michael Brundage, Erica L. Harnett, Lois Shepherd, Judy-Anne W. Chapman, Ralph M. Meyer
Journal: Blood
Blood (2013) 121 (9): 1517–1523.
https://doi.org/10.1182/blood-2012-09-451872
Published: 2013
Journal Articles

Phase II Testing of Lenalidomide Plus Melphalan for Previously Untreated Older Patients with Multiple Myeloma: The NCIC CTG MY.11 Trial

Darrell J White, MD, Nizar J Bahlis, MD, Deborah C Marcellus, MD, Andrew Belch, MD, A. Keith Stewart, MBChB, MBA, Christine Chen, MD, Michael J Kovacs, MD, David A Macdonald, MD, Donna E Reece, MD, Erica Harnett, MSc, Judy-Anne W Chapman, PhD, Ralph M Meyer, MD
Journal: Blood
Blood (2008) 112 (11): 2767.
https://doi.org/10.1182/blood.V112.11.2767.2767
Published: 2008
Journal Articles

Tolerability and Efficacy of Bortezomib Added to CVP-R for Previously Untreated Advanced Stage Follicular Lymphoma: Interim Analysis of a Phase II Study by the NCIC Clinical Trials Group.

Laurie H Sehn, MD, MPH, David A Macdonald, MD, Sheldon H. Rubin, MD, Morel Rubinger, MD, FRCPC, Kevin R Imrie, MD, Judy-Anne W Chapman, PhD, Marina Djurfeldt, Lois Shepherd, MD, Stephen Couban, MD, Michael Crump, MD
Journal: Blood
Blood (2008) 112 (11): 1576.
https://doi.org/10.1182/blood.V112.11.1576.1576
Published: 2008
Journal Articles

Phase II Testing of Lenalidomide Plus Melphalan for Previously Untreated Older Patients with Multiple Myeloma: Toxicity Data from the NCIC CTG MY.11 Trial.

Darrell J. White, MD, Michael J. Kovacs, MD, Andrew Belch, MD, Keith Stewart, MB, ChB, Christine Chen, MD, Sheldon Rubin, MD, David A. Macdonald, MD, Erica Harnett, MSc, Judy-Anne W. Chapman, PhD, Lois E. Shepherd, MD, Ralph M. Meyer, MD
Journal: Blood
Blood (2007) 110 (11): 189.
https://doi.org/10.1182/blood.V110.11.189.189
Published: 2007
Journal Articles

Maintenance Therapy with Thalidomide/Prednisone Post Autologous Stem-Cell Transplant for Patients with Multiple Myeloma Elevates D-Dimer and Possibly Factor VIII Levels.

Michael J. Kovacs, MD, FRCPC, Judy-Anne W. Chapman, PhD, Lois Shepherd, MD, FRCPC, Ralph Meyer, MD, FRCPC, Michael Keeney, ART, FIMLS, Karen MacKinnon, MLT, Keith Stewart, MD, FRCPC, Nancy Paul, PhD, The NCIC CTG Investigators on MY.10.
Journal: Blood
Blood (2005) 106 (11): 2561.
https://doi.org/10.1182/blood.V106.11.2561.2561
Published: 2005